Surgical Menopause Raises Vaginal Atrophy Risk

Vaginal Atrophy After Menopause: Surgical Menopause Carries a Greater Risk

The loss of estrogen after menopause causes thinning, drying, and inflammation in vaginal and urinary tissues, a condition now called genitourinary syndrome of menopause (GSM). New research from Torbali State Hospital in Turkey suggests the type of menopause matters: women who undergo surgical removal of their ovaries face a more severe form of GSM than those experiencing natural menopause.

Surgical Menopause Associated with More Severe GSM

A study led by Dr. Sule Ozmen and colleagues compared 422 postmenopausal women, 218 with surgical menopause and 204 with natural menopause. The team used a standardized eight-component physical exam to assess GSM objectively, scoring factors like tissue elasticity, lubrication, integrity, and urethral appearance. Women who had surgical menopause had significantly higher total scores, indicating worse atrophy.

This group also reported more frequent and severe symptoms. Specifically, genital dryness, pain during sex (dyspareunia), reduced sexual desire, postcoital bleeding, painful urination (dysuria), and urinary frequency were all more common among those with surgical menopause. A regression analysis confirmed that surgical menopause was independently associated with a higher GSM score, regardless of other factors like age or time since menopause.

The likely mechanism is abruptness. Natural menopause involves a gradual, multi-year decline in estrogen, allowing some physiological adaptation. Surgical menopause, however, creates an immediate, complete hormone withdrawal. This sudden deprivation appears to trigger more dramatic and rapid deterioration of estrogen-sensitive tissues.

Vaginal Tamoxifen May Offer Relief Beyond Physical Symptoms

While local estrogen therapy remains a first-line treatment for GSM, it is not suitable for everyone, especially some breast cancer survivors. This has driven research into non-estrogen alternatives. One candidate, vaginal tamoxifen, was examined in a separate study by a European team including Theodora Kunovac Kallak from Uppsala University.

Vaginal tamoxifen, a selective estrogen receptor modulator, works locally in vaginal tissues. Researchers previously established its effectiveness for GSM symptoms. Their new work explored its impact on mental health, finding that women treated with vaginal tamoxifen reported reduced symptoms of anxiety and depression and an improved health-related quality of life compared to those using a placebo.

This finding is notable. The discomfort of GSM—painful sex, constant irritation, urinary urgency—can directly erode mental well-being and self-esteem. A treatment that addresses the physical cause may therefore create a positive ripple effect on psychological health.

Objective Assessment Tools Can Guide Timely Care

A key element from the Turkish study is the validation of a practical, 22-point clinical scoring system. This tool moves beyond subjective symptom reporting to give clinicians an objective measure of tissue health. It assesses eight specific components: elasticity, lubrication, tissue integrity, introital width, labial atrophy, urethral appearance, vaginal rugae, and color.

For patients, this means a more precise diagnosis. A score can help a doctor determine if symptoms are mild, moderate, or severe. It also provides a baseline to measure the effectiveness of interventions over time, whether with estrogen, vaginal tamoxifen, or other strategies. The researchers advocate for integrating this or similar standardized exams into routine gynecological care, especially for women who have had surgical menopause.

It also underscores that GSM is a diagnosable medical condition, not an inevitable nuisance. As with other menopausal health issues like bone loss, objective measurement supports proactive management.

Navigating Treatment Options for Vaginal Atrophy

These studies reinforce that GSM is highly treatable. The first step is an open conversation with a healthcare provider. For many women, low-dose vaginal estrogen (creams, rings, or tablets) is safe and highly effective. For those who cannot or prefer not to use estrogen, the data on vaginal tamoxifen is encouraging, though its availability may vary.

Non-hormonal moisturizers and lubricants provide symptom relief for some. Pelvic floor physical therapy can also be beneficial, especially when pain is a primary feature. The link between GSM and reduced sexual desire highlights how these physical changes can intersect with hormonal shifts in libido, a topic explored in our article on testosterone and female libido.

Women experiencing surgical menopause should be particularly vigilant. Their heightened risk for severe GSM makes post-operative discussions about vaginal and urinary health a necessity, not an afterthought.

Vaginal atrophy is a direct consequence of estrogen loss, but its severity is not uniform. Surgical menopause demands special clinical attention. The emergence of objective scoring tools and new treatment avenues like vaginal tamoxifen offers hope for more personalized and effective care, aiming to restore both physical comfort and overall quality of life.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42262430/
https://pubmed.ncbi.nlm.nih.gov/42235095/
https://pubmed.ncbi.nlm.nih.gov/42234022/